Markets Stumble: Apple Slips, Meta Soars, GLP-1 Risks

MARKET RECAP & OUTLOOK

Market Pulse: Benchmarks drifted lower as hefty AI budgets at Big Tech fueled profit-taking across sectors, sending the S&P and Nasdaq into the red.

Key Movers: Apple’s late-session guidance flip sent U.S. futures tumbling after a stellar earnings beat (AAPL stock price surges today after Apple earnings beat estimates – The Times of India), while Meta’s post-earnings pop (Mark Zuckerberg Passes Jeff Bezos For No. 4 Richest As Meta Stock Soars On Earnings Beat – Forbes) underscores this whipsaw environment.

Macro & Politics: Tom O’Brien warns Ireland must pick a side in the US-Europe tax standoff (Tom O’Brien of Forvis Mazars: Ireland must ‘come down on one side’ of the US-Europe divide – The Irish Times), a reminder that digital-tax retaliation risks could ricochet through global multinationals.

What’s Next: Today’s open looks set for more red—keep an eye on tech names and GLP-1 stocks after Goldman flagged a dip-buying chance (Goldman Says “Good Opportunity To Buy Dip” In Obesity Drug Stocks – Zerohedge.com).

MARKET COMMENTARY

What everyone’s missing is that regulatory hurdles and quirky supply cycles can knock the GLP-1 rally off its perch overnight, despite Goldman’s “good opportunity to buy dip” call (Goldman Says “Good Opportunity To Buy Dip” In Obesity Drug Stocks – Zerohedge.com). Everyone’s chasing that obesity-drug mania without considering how FDA timing or plant bottlenecks could slam the brakes on these names.

It’s easy to treat Big Tech AI budgets and tokenized asset growth as separate stories, but both hinge on overblown expectations. After “S&P 500, Nasdaq close down as Big Tech’s soaring AI budgets trigger flight” (The Times of India) and “Tokenization firm Securitize reports 841% revenue growth as it prepares to go public” (CoinDesk), you see one sector burning cash on AI while another floods the market with hype-driven issuance—classic froth.

Adjust your game plan: trim positions that are riding sentiment, not sustainable catalysts, and focus on clear trigger events—Apple’s next guidance update, FDA green lights on new GLP-1 drugs, or any real revenue beats in tokenized assets. This is the moment to get surgical, not sentimental.